News

Deal Announcements

Ardelyx Closes $30 Million Series B Funding

Thursday, September 1, 2011 5:34:00 AM PDT | VentureDeal Staff
   Fremont, California  --  Biotechnology company Ardelyx has secured $30 million in its second round of institutional venture capital investment.

Ardelyx is developing drugs that target specific gut transporters and receptors in the treatment of chronic diseases.

Investors in the round included New Enterprise Associates, CMEA Capital and Amgen Ventures.

The company said it would use the financing to advance its clinical pipeline.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1